This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. http://www.researchmoz.us/seborrhea-pipeline-review-h1-2015-report.html

1. Seborrhea - Pipeline Review, H1 2015
Global Markets Directs, Seborrhea Pipeline Review, H1 2015, provides an overview of the Seborrheas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued
projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Seborrhea The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved
in the therapeutics development for Seborrhea and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline
projects A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company
and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed
stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Seborrhea pipeline on the basis of target, MoA, route of
administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Seborrhea Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Seborrhea
pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding
the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 4
introduction 5
global Markets Direct Report Coverage 5
seborrhea Overview 6
therapeutics Development 7
pipeline Products For Seborrhea - Overview 7
pipeline Products For Seborrhea - Comparative Analysis 8
seborrhea - Therapeutics Under Development By Companies 9
seborrhea - Pipeline Products Glance 10
clinical Stage Products 10
early Stage Products 11
seborrhea - Products Under Development By Companies 12
seborrhea - Companies Involved In Therapeutics Development 13
biomar Microbial Technologies 13
epipharm Ag 14
maruho Co., Ltd. 15
phosphagenics Limited 16
seborrhea - Therapeutics Assessment 17
assessment By Monotherapy Products 17
assessment By Target 18
assessment By Mechanism Of Action 19
assessment By Route Of Administration 20
assessment By Molecule Type 21
drug Profiles 22
a-101 - Drug Profile 22
Seborrhea - Pipeline Review, H1 2015

2. product Description 22
mechanism Of Action 22
r&d Progress 22
epi-sk14 - Drug Profile 23
product Description 23
mechanism Of Action 23
r&d Progress 23
ib-07a081 - Drug Profile 24
product Description 24
mechanism Of Action 24
r&d Progress 24
ib-07a085 - Drug Profile 25
product Description 25
mechanism Of Action 25
r&d Progress 25
ketoconazole - Drug Profile 26
product Description 26
mechanism Of Action 26
r&d Progress 26
lanoconazole - Drug Profile 27
product Description 27
mechanism Of Action 27
r&d Progress 27
seborrhea - Recent Pipeline Updates 28
seborrhea - Dormant Projects 29
seborrhea - Discontinued Products 30
seborrhea - Product Development Milestones 31
featured News & Press Releases 31
jan 27, 2015: Aclaris Therapeutics Announces Positive Results From Phase 2b Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common
Type Of Benign Skin Tumor 31
jun 30, 2014: Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common
Type Of Skin Tumor 31
appendix 33
methodology 33
coverage 33
secondary Research 33
primary Research 33
expert Panel Validation 33
contact Us 33
disclaimer 34
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Seborrhea - Pipeline Review, H1 2015